JP Morgan Chase
MDNA

JP Morgan Chase’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

JP Morgan Chase’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-25,500
Closed -$77K – 6929
2021
Q2 		$77K Buy
25,500
+16,100
+171% +$59.6K ﹤0.01% 5628
2021
Q1 		$38K Buy
9,400
+5,333
+131% +$21.7K ﹤0.01% 5596
2020
Q4 		$19K Sell
4,067
-18,133
-82% -$73.1K ﹤0.01% 5309
2020
Q3 		$104K Buy
+22,200
New +$89.3K ﹤0.01% 4671

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

JP Morgan Chase's MDNA Position: Q3 2021 in Review

JP Morgan Chase sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q3 2021, closing a stake of 25,500 shares — an estimated $77K sold.

JP Morgan Chase first reported a position in MDNA in Q3 2020 and held it in 4 quarters. The position peaked at $104K in Q3 2020. 25 funds tracked by Wall St. Rank hold MDNA as of Q3 2021.

  • JP Morgan Chase reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q3 2021 after selling out during the quarter.
  • JP Morgan Chase sold 25,500 Medicenna Therapeutics Corp. Common Shares shares in Q3 2021, an estimated $77K.
  • JP Morgan Chase first reported a position in Medicenna Therapeutics Corp. Common Shares in Q3 2020 and held it in 4 quarters.
  • JP Morgan Chase's Medicenna Therapeutics Corp. Common Shares position peaked at $104K in Q3 2020.
  • 25 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q3 2021.

Based on JP Morgan Chase's 13F filing for Q3 2021, filed 12 Nov 2021.